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Background: Primate-specific melanoma antigen-A11 (MAGE-A11) increases steroid receptor transcriptional activity and
enhances prostate cancer cell growth.
Results:MAGE-A11 activates E2F1 by interacting with retinoblastoma-related protein p107.
Conclusion:MAGE-A11 influences cell cycle regulatory pathways in a molecular hub for transcription.
Significance: MAGE-A11 is a proto-oncogene whose increased expression impacts multiple signaling mechanisms that con-
tribute to prostate cancer growth and progression.
Melanoma antigen-A11 (MAGE-A11) is a low-abundance,
primate-specific steroid receptor coregulator in normal tis-
sues of the human reproductive tract that is expressed at
higher levels in prostate cancer. Increased expression ofMAGE-
A11 enhances androgen receptor transcriptional activity and
promotes prostate cancer cell growth. Further investigation into
the mechanisms of MAGE-A11 function in prostate cancer
demonstrated interactions with the retinoblastoma-related
protein p107 and Rb tumor suppressor but no interaction with
p130 of the Rb family. MAGE-A11 interaction with p107 was
associated with transcriptional repression in cells with low
MAGE-A11 and transcriptional activation in cells with higher
MAGE-A11. Selective interaction of MAGE-A11 with retino-
blastoma family members suggested the regulation of E2F tran-
scription factors. MAGE-A11 stabilized p107 by inhibition of
ubiquitination and linked p107 to hypophosphorylated E2F1 in
association with the stabilization and activation of E2F1. The
androgen receptor and MAGE-A11 modulated endogenous
expression of the E2F1-regulated cyclin-dependent kinase
inhibitor p27Kip1. The ability of MAGE-A11 to increase E2F1
transcriptional activity was similar to the activity of adenovirus
early oncoprotein E1A and depended on MAGE-A11 interac-
tions with p107 and p300. The immunoreactivity of p107 and
MAGE-A11 was greater in advanced prostate cancer than in
benign prostate, and knockdown with small inhibitory RNA
showed that p107 is a transcriptional activator in prostate can-
cer cells. These results suggest that MAGE-A11 is a proto-onco-
gene whose increased expression in prostate cancer reverses reti-
noblastoma-related protein p107 from a transcriptional repressor
to a transcriptional activator of the androgen receptor and E2F1.
Melanoma antigen-A11 (MAGE-A11)4 is a primate-specific
steroid hormone receptor coregulator that increases transcrip-
tional activity of the human androgen receptor (AR) (1) and
isoform B of the human progesterone receptor (2). The effects
of MAGE-A11 are mediated by interactions with p160 coacti-
vators and p300 acetyltransferase (3, 4). MAGE-A11 interacts
with the NH2-terminal FXXLF motif region of human AR that
overlaps with the androgen-dependent NH2- and carboxyl-ter-
minal interaction important for AR transcriptional activity (1,
5–8).MAGE-A11 also interacts with an extended LXXLLmotif
region in the NH2-terminal region of human progesterone
receptor B, which is absent in the otherwise identical shorter
progesterone receptor A (2). Lowermammals, such as mice, do
not have the MAGE-A11 gene. Sequence differences in the
FXXLF motif region of the mouse AR inhibit an interaction
with MAGE-A11 (9). These findings suggest that the evolution
of MAGE-A11 in primates provides greater regulatory control
of steroid receptor transcriptional activity. It was shown
recently that MAGE-A11 enhances human AR transcriptional
activity by bridging AR dimers in a mechanism that accounts
for the dual functions of the AR FXXLF motif in the androgen-
dependent AR NH2- and carboxyl-terminal interaction and
binding to MAGE-A11 (10).
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MAGE-A11 is a member of a family of cancer-testis antigen
genes that are frequently overexpressed in cancer (11).MAGE-
A11 is also expressed at low levels in normal tissues of the
human male and female reproductive tracts. It was first identi-
fied as an AR-interacting protein in human testis and is present
at low levels in human foreskin fibroblasts (1). MAGE-A11
expression is regulated hormonally in human endometrium
during the menstrual cycle and up-regulated by cyclic AMP
(12).MAGE-A11 expression is cell cycle-dependent (4), and its
coregulator activity depends on Chk1, a cell cycle-dependent
kinase that phosphorylates a threonine residue in the relatively
conserved carboxyl-terminal MAGE homology domain that
characterizes this gene family (13). MAGE-A11 mRNA can
increase exponentially during prostate cancer progression to
castration-recurrent growth (10, 11, 14). Inhibition of MAGE-
A11 expression arrests the growth of androgen-stimulated
prostate cancer cells (10).
The family of retinoblastoma proteins includes the retino-
blastoma (Rb) tumor suppressor, p107 (also known as Rb-like
protein 1 (pRb1)), and p130 (pRb2). Rb-like proteins suppress
cell growth by restricting progression through the G1/S transi-
tion of the cell cycle by interacting through their so-called
pocket regions to negatively regulate E2F transcription factors
(15–17). Rb-related proteins are regulated by phosphorylation
(18), and hypophosphorylated retinoblastoma proteins bind
E2Fs to inhibit transcription. Phosphorylation by cyclin-depen-
dent kinases in normally cycling cells releases bound E2Fs in a
cell cycle-dependent manner (19). At least eight E2F transcrip-
tion factors expressed inmammalian cells have been grouped as
transcriptional activators or repressors (20).
The tumor suppressor function of Rb is often lost in late-
stage cancer because of mutations in the pocket region that
interfere with suppression of E2F transcriptional activity (21).
In contrast,mutations in p107 have not been reported in cancer
(21, 22), althoughp107 is important for cell cycle regulation (23,
24). Loss of Rb-related protein activity is also achieved by can-
cer cells through the action of viral oncogenes that target the
pocket region (25, 26). One of these viral proteins, human ade-
novirus type 5 early region 1A (E1A), is important in cell trans-
formation. E1A disrupts Rb-related protein complexes through
competitive binding and release of transcriptionally active E2Fs
that regulate genes that control the cell cycle (27–29). E1A dis-
places E2F transcription factors from all three Rb-related pro-
teins and induces entry into S phase of the cell cycle.
In this report, we investigatedmechanisms bywhichMAGE-
A11 contributes to prostate cancer cell growth. We show that
MAGE-A11 selectively regulates retinoblastoma family members
through mechanisms similar to the adenoviral oncoprotein E1A.
MAGE-A11 interacts with p107 and increases E2F1 transcrip-
tionalactivity.Stabilizationofp107byMAGE-A11correlatedwith
increased p107 immunostaining in prostate cancer and acquisi-
tion of p107 transcriptional activator activity.
EXPERIMENTAL PROCEDURES
DNA Vectors—Human AR expression vectors included
pCMV-hAR coding for 919-amino acid, full-length AR (30);
pCMV-FLAG-AR (1); and pCMV-AR-(1–660) with AR NH2-
terminal and DNA binding domains (31). Human MAGE-A11
expression vectors included pSG5-MAGE coding for 429-a-
mino acid, full-length human MAGE-A11; pCMV-FLAG-
MAGE; pCMV-FLAG-MAGE-(112–429) (1); and MAGE-A11
mutants in pSG5-MAGE and pSG5-HA-MAGE-(112–429),
pSG5-HA-MAGE-(112–307), and pSG5-HA-MAGE-(112–
298) with the human influenza HA tag (3, 4, 13). pSG5-HA-
MAGE was created by PCR-amplifying pSG5-MAGE and
inserting the fragment with EcoRI and SalI ends into the EcoRI
and XhoI sites of pSG5-HA. Other expression vectors included
pSG5-HA-p300 (4), pCMV-Rb (provided by Yue Xiong) (32),
pcDNA3-p130 (33), pCMV-FLAG-ubiquitin (13), and CMX-
E1A variant C (provided by Hong-Wu Chen) (34). CMV-neo-
p107 (CMV-p107) expresses full-length human p107, and
CMV-p107DE (CMV-p107409–826) has a deletion in the
pocket region (35). CMV-p107-(1–385) and CMV-p107-(385–
1068) were provided by Joan Massagué (36). CMV-p107-(1–
180) was constructed by cloning an EcoRI and BamHI fragment
PCR-amplified from CMV-HA-p107-(1–385) into the same
sites of pCMV-HA. All PCR-amplified regions were verified
using DNA sequencing.
Luciferase reporter vectors included the prostate-specific
antigen (PSA) enhancer luciferase PSA-Enh-Luc (4, 37) and
E2F1-Luc, which contains the 728 nucleotide E2F1 promoter
region in pGL2. E2F1-Luc(-E2F) is the same as E2F1-Luc,
except for inactivating mutations in three E2F1 binding sites.
E2F4-Luc contains a 3-kb E2F4 promoter fragment in pGL2
basic. E2F reporter vectors were provided by Joseph R. Nevins
(38).
Expression Studies—Cells were grown inmedium containing
penicillin, streptomycin, and 2 mM L-glutamine (Invitrogen).
Human cervical carcinoma HeLa and HeLa-AR3A-PSA-ARE4
cells that stably express human AR (39) were propagated in
minimal essential medium containing 10% fetal bovine serum.
Monkey kidney CV1 and COS1 cells were maintained in Dul-
becco’s modified essential medium with 10% bovine calf serum
and 20mMHepes (pH 7.2). LAPC-4 human prostate cancer cells
were grown inRPMI1640mediumwith 10% fetal bovine serum, 1
mM sodium pyruvate, and 1 nM methyltrienolone R1881, a syn-
thetic androgen. HEK293 cells were maintained in Eagle’s mini-
mum essential mediumwith 10% fetal bovine serum.
HeLa (5  104 cells/well) and CV1 cells (104 cells/well) in
12-well plates were transfected with expression and luciferase
reporter DNA using X-tremeGENE 9 or FuGENE 6 (Roche
Applied Science) (10). After 24 h, cells were transferred to
serum-free, phenol red-freemediumwith orwithout 1 nMdihy-
drotestosterone (DHT). siRNAs for E2F1 and p107 (Dharma-
con RNA Technologies) were expressed in LAPC-4 (3.8  105
cells/well) or COS1 cells (4.5 105 cells/well) in 6-well plates in
1 ml of medium without antibiotics using Lipofectamine 2000
(Invitrogen) (3, 4). Cells in 6- and 12-well plates were harvested
in 0.25 ml of 1% Triton X-100, 2 mM EDTA, and 25 mM Tris
phosphate (pH 7.8). Luciferase activity (mean  S.D.) was
measured in 0.1-ml aliquots using an automated Lumistar Gal-
axy luminometer. Data are representative of at least three inde-
pendent experiments.
Immunoblots of extracts from COS1 cells (2  106 cells/
10-cm dish, 7  105 cells/6-cm dish) transfected using DEAE-
dextran were prepared in immunoblot lysis buffer containing
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1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 0.15 M
NaCl, 2 mM EDTA, 50 mMNaF, 2 mM sodium vanadate, 50 mM
Tris-HCl (pH 7.5), 1 mM phenylmethylsulfonyl fluoride, 1 mM
dithiothreitol, and protease inhibitors (RocheApplied Science).
Immunoprecipitation of endogenous and expressed proteins
was performed by transfecting pCMV-FLAG vectors in 10-cm
dishes containing 2  106 COS1 or 1.5  107 HEK293 cells
using DEAE-dextran (40, 41) or 7  106 LAPC-4 cells using
X-tremeGENE 9. After 24 h in serum-free medium, cells were
harvested in phosphate-buffered saline. Cell pellets were
extracted in immunoprecipitation lysis buffer containing 1%
TritonX-100, 0.15 MNaCl, 50mMNaF, 2mM sodium vanadate,
2 mM EDTA, 50 mM Tris (pH 7.6), 1 mM phenylmethylsulfonyl
fluoride, 1 mM dithiothreitol, and complete protease inhibitors
(Roche Applied Science) with or without 0.5% deoxycholate or
10% glycerol. Samples containing deoxycholate were diluted
4-fold with lysis buffer without deoxycholate. Samples were
precleared for 15 min at 4 °C using Sepharose CL-4B (Sigma)
and immunoprecipitated for 2 h at 4 °C using anti-FLAG
M2-agarose affinity resin (9). For phosphorylation experi-
ments, 30 g of cell extract protein in 40 l of immunoprecipi-
tation buffer without NaF, sodium vanadate, EDTA, or deoxy-
cholate was incubated for 1 h at 4 °C with or without 4000 IU 
protein phosphatase (New England Biolabs), according to the
instructions of the manufacturer (3).
Endogenous expression of AR andMAGE-A11was inhibited
in LAPC-4 cells using lentivirus shRNA prepared using the
Open Biosystems TRC1 shRNA library. HEK293 cell medium
(0.15–0.3 ml) containing 106 lentivirus particles/ml was
added to LAPC-4 cells (107/10-cmdish) plated the day before in
6 ml of growth medium. Cells were incubated for 48 h at 37 °C
with lentivirus for MAGE-A11 shRNA-947, 169, and 827; AR
shRNA-5; a nonspecific 18-bp spacer; and empty lentivirus
controls. Cells were harvested using trypsin-EDTA and plated
in 10-cm dishes in medium containing 3 g/ml puromycin
dihydrochloride (Cellgro) for cell selection after lentivirus
transduction. After 4 days in culture, cells were incubated with
10 nM DHT for 24 h and extracted using immunoblot lysis
buffer.
Acrylamide gels (8 or 10%) containing SDS were calibrated
using dual color Precision Plus protein standards (Bio-Rad).
Immunoblots were probed using the following antibodies from
Santa Cruz Biotechnology, Inc. at 1:200 dilution unless indi-
cated otherwise: p107 C-18 (sc-318) affinity-purified rabbit
polyclonal antibody to a carboxyl-terminal human p107 pep-
tide, E2F1 KH95 (sc-251) mouse monoclonal antibody to
human E2F1 amino acid residues 342–386, E2F1 C-20 (sc-193)
rabbit polyclonal antibody to a carboxyl-terminal epitope, E2F4
C-108 (sc-512) rabbit polyclonal antibody to human E2F4
amino acid residues 108–300, p130 C-20 (sc-317) affinity-pu-
rified rabbit polyclonal antibody to a human p130 carboxyl-
terminal peptide, and DP-1 K-20 (sc-610) rabbit polyclonal
antibody. Additional antibodies included MAGE-A11 rabbit
polyclonal antibody against FLAG-tagged human MAGE-A11
expressed in baculovirus (0.2 g/ml for expressed MAGE-A11
and 10 g/ml for endogenous MAGE-A11), AR32 rabbit poly-
clonal antibody to human AR 9–28 amino acid peptide (1
g/ml) (42), AR52 rabbit polyclonal antibody to human AR
544–558 amino acid peptide (10 g/ml) (30), anti-FLAG M2
F3165 monoclonal antibody (Sigma, 1:2000 dilution), Rb Ab-1
clone 1F8 mouse monoclonal antibody to human Rb amino
acid residue epitope 703–722 (Thermo Scientific, 1:500 dilu-
tion), p27Kip1 (p27) purifiedmouse antibody (BDTransduction
Laboratories, 1:50 dilution), and rabbit polyclonal HA antibody
ab9110 (Abcam, 1:1000 dilution). In some experiments, blots
were stripped by incubating for 23 min using a hybridization
rotator at 55 °C in 10 ml of prewarmed 2% SDS, 62.5 mM Tris-
HCl (pH 6.7) containing 64 l of -mercaptoethanol and rep-
robing with antibody.
Quantitative Real-time RT-PCR—LAPC-4 cells (2.4  106
cells/6-cm dish) plated in growthmedium containing 10% fetal
calf serumwere grown for at least 48 h to50% confluence and
transferred to serum-free medium. The next day, cells were
placed in medium containing 5% charcoal-stripped serum and
incubated with or without DHT. Cells were harvested in 1 ml
TRIzol reagent (Invitrogen). RNA was isolated using chloroform
extraction and precipitated using isopropanol. First-strand cDNA
was prepared using SuperScript II reverse transcriptase (Invitro-
gen) and oligo(dT) primer. Real-time PCR was performed using
an Applied Biosystems StepOnePlus real-time PCR system
and p27 forward primer 5-GTTAACCCGGGACTTGGA-3
and p27 reverse primer 5-CACCTCTTGCCACTCGTA-3 and
peptidylprolyl isomerase A housekeeping control forward primer
5-ATCTTGTCCATGGCAAATGC-3 and reverse primer 5-
GCCTCCACAATATTCATGCC-3 (Integrated DNA Tec-
hnologies). Reactions (20 l) contained 4 l of cDNA (40 ng),
10 l of Sso Advanced SYBR Green Supermix (Bio-
Rad), 0.4 l of ROX reference dye (Invitrogen), 2 l of 2 M
amplification primers, and 1.6l of RNase-free H2O. Real-time
PCRamplificationwas 1 cycle at 95 °C for 20min followed by 45
cycles at 95 °C for 30 s, 57.5 °C for 30 s, 72 °C for 40 s, and 79 °C
for 20 s. p27 and peptidylprolyl isomerase A standard curves
were performed on the basis of 10-fold dilutions of cDNA.
Cell Growth Assays—LAPC-4 cells (4  105 cells/well) were
plated in triplicate in 24-well plates in 0.5 ml of medium con-
taining 10% charcoal-stripped serum without phenol red. The
next day and 3 days later, 100 l of serum-free medium with or
without DHT were added. Cells were harvested daily, begin-
ning 24 h after the first addition of DHT, by aspirating the
medium and adding 0.2 ml of serum-free medium and 20 l of
cell counting kit 8 reagent (Dojindo Laboratories). After 2.5 h at
37 °C, 0.1 ml was analyzed spectrophotometrically at 485 nm.
Immunostaining—Benign prostate and prostate cancer tis-
sues were obtained from prostatectomy specimens after
informed consent and approval by institutional review boards
at the University of North Carolina at Chapel Hill. Adjacent
formalin-fixed, paraffin-embedded, 8-m sections of andro-
gen-stimulated benign prostate and androgen-stimulated and
castration-recurrent prostate cancer were immunostained for
endogenous p107 and MAGE-A11 using affinity-purified
human p107 rabbit antibodyC-18 (sc-318, 1:100 dilution, Santa
Cruz Biotechnology) and affinity-purified human MAGE-A11
rabbit polyclonal anti-peptide MAGE-(94–108) antibody (6
g/ml). Sections were pretreated with 4% H2O2 in 83% metha-
nol for 30 min at room temperature, blocked using 2% goat
serum, incubated overnight with primary antibody at 4 °C,
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blocked, and incubated for 30 min with biotinylated rabbit sec-
ondary antibody at room temperature. This was followed by 30
min with avidin DH-biotinylated horseradish peroxidase H
complex using the Vectastain Elite ABC kit (Vector Laborato-
ries). Slides were incubated for 10min using theVector Laborato-
ries peroxidase 3,3-diaminobenzidine substrate kit and counter-
stained using 0.05% toluidine blue in 30% ethanol (14). Images
were captured using a SPOT Insight-4 camera (Diagnostic Instru-
ments) and a Nikon Eclipse E600microscope.
RESULTS
Regulation of HumanARTranscriptional Activity byMAGE-
A11 and p107—MAGE-A11 is expressed at very low levels in
normal tissues of the human male reproductive tract and at
higher levels in prostate cancer, where it increases AR tran-
scriptional activity (4, 10, 11, 14). MAGE-A11 influences AR
levels in the absence and presence of androgen (1). To explore
the mechanisms by which MAGE-A11 increases AR signaling
in prostate cancer, we investigated the effects on the retinoblas-
toma family. Initial studies were performed in CV1 cells that do
not express MAGE-A11, HeLa cells with lower MAGE-A11
expression, and LAPC-4 prostate cancer cells with higher
MAGE-A11 expression (14).
MAGE-A11 and p300 increased androgen-dependent AR
transactivation of the prostate-specific antigen enhancer in
CV1 cells (Fig. 1A), as reported previously (4, 9). p107 inhibited
the increase in AR activity byMAGE-A11 and p300 but did not
inhibit AR activity without expressing MAGE-A11 and p300.
AR activity was not inhibited by p130, another member of the
Rb family, with or without MAGE-A11 and p300 (Fig. 1A). In
HeLa cells with lowMAGE-A11 expression relative to LAPC-4
cells (Fig. 1B), low levels of p107 slightly stimulated AR activity
in the presence of MAGE-A11, but higher levels of p107 were
inhibitory with or without MAGE-A11 (C). In contrast, the
highest amounts of p107 that inhibited theMAGE-A11-depen-
dent increase in AR activity in CV1 orHeLa cells did not inhibit
AR in LAPC-4 cells (Fig. 1F, right).
The influence ofMAGE-A11 and p107 onAR transcriptional
activity was investigated further using a constitutively active
AR-(1–660) NH2-terminal and DNA binding fragment that
contains NH2-terminal activation function 1 and the FXXLF
motif region that interacts with MAGE-A11 but lacks the AR
ligand binding domain (1, 31). AR-(1–660) is similar to splice
variants reported at low levels in prostate cancer (43, 44). Sim-
ilar to full-length AR, p107 inhibited AR-(1–660) activity in a
dose-dependent manner in HeLa cells with or without MAGE-
A11 (Fig. 1, D and E). In contrast, p107 slightly increased
AR-(1–660) activity in LAPC-4 cells (Fig. 1F, left).
The ability of p107, but not p130, to influence MAGE-A11
activation of the AR suggests that MAGE-A11 interacts selec-
tively with Rb-related proteins. This possibility was investi-
FIGURE 1. Inhibition of MAGE-A11-dependent AR transcriptional activity by p107. A, pCMV5 (p5) or pCMV-AR (25 ng) was expressed in CV1 cells with 0.25
g of PSA-Enh-Luc and 25 ng of empty vector (), CMV-p107, or pcDNA3-p130 with or without 50 ng of pSG5-MAGE (M) and 50 ng pSG5-HA-p300 (P). Cells
were plated in medium containing 5% charcoal-stripped serum and incubated for 24 h the day after transfection with or without 1 nM DHT. B, LAPC-4 (LA, lane
1) and HeLa (HL, lane 2) cell extracts (80 g of protein/lane) from cells cultured in serum-free medium for 24 h before harvest were prepared in immunoblot lysis
buffer. Lane 3 contains 0.1 g of protein extract from COS1 cells (C) expressing pSG5-MAGE. The immunoblot was probed using 10 g/ml MAGE-A11 antibody.
C, pCMV-AR (25 ng) was expressed in HeLa cells with 0.1 g of PSA-Enh-Luc and 50 ng of pSG5 () or pSG5-MAGE with or without 50 ng of pSG5 () or 10, 25,
or 50 ng of CMV-p107. Cells were incubated with or without 1 nM DHT. D, pCMV5 (25 ng) or 25 ng of pCMV-AR-(1– 660) was expressed in HeLa cells with 0.1 g
of PSA-Enh-Luc with or without 50 ng of pSG5-MAGE and pCMV5 (), CMV-p107 and pSG5 (), or pSG5-MAGE and CMV-p107. E, pCMV5 or pCMV-AR-(1– 660)
(10 ng) was expressed in HeLa cells with 0.1 g of PSA-Enh-Luc, 50 ng of pSG5 () or pSG5-MAGE, and 50 ng of p5 () or 10, 25, or 50 ng of CMV-p107. F, pCMV5
(5 ng) (), 5 ng of pCMV-AR-(1– 660), or 25 ng of pCMV-AR was expressed in LAPC-4 cells with 0.1 g of PSA-Enh-Luc and 50 ng of pCMV5 () or 50 ng of
CMV-p107. Cells were incubated with or without 1 nM DHT. In A and C–F, luciferase activity is the mean  S.D. (error bars) and representative of three
experiments.
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gated by comparing the immunoprecipitation of p107, Rb, and
p130 with FLAG-MAGE or FLAG-MAGE-(112–429), a car-
boxyl-terminal fragment with the conserved MAGE homology
domain (13). FLAG-MAGE was used because endogenous
MAGE-A11 levels were low. p107 (Fig. 2A) and, to a lesser
extent, Rb (B) immunoprecipitated with FLAG-MAGE and
FLAG-MAGE-(112–429). In contrast, p130 did not associate
with either form of FLAG-MAGE (Fig. 2C). The specificity of
MAGE-A11 interaction with Rb-related proteins was consist-
ent with the ability of p107, but not p130, to modulate the
MAGE-A11-dependent increase in AR activity.
The results suggest that MAGE-A11 interacts preferentially
with p107, less with Rb, and does not interact with p130 of the
Rb family. The specificity of MAGE-A11 interaction with Rb-
like proteins supported the physiological relevance of MAGE-
A11 interaction with p107 and modulation of transcriptional
activity.
MAGE-A11 Mediates an Interaction between AR and p107—
The modulation of AR transcriptional activity by MAGE-A11
and p107 suggests that MAGE-A11 might mediate an interac-
tion between these proteins, which was investigated by immu-
noprecipitation of MAGE-A11 and p107 with FLAG-AR.
MAGE-A11 associated with FLAG-AR with or without p107
(Fig. 3, lanes 10–17), which agreed with previous findings (1).
However, an interaction between FLAG-AR and p107 was seen
only when MAGE-A11 was expressed (Fig. 3, lanes 6–13).
Treatment with EGF, a growth factor that increases phosphor-
ylation in the MAGE homology domain and enhances MAGE-
A11 interaction with the AR (13), promoted the MAGE-A11-
dependent interaction between the AR and p107 (Fig. 3, lanes
10–13).
p107 has multiple interaction domains for regulatory pro-
teins similar, but not identical, to other retinoblastoma family
members (Fig. 4A). The domains of p107 that interact with
MAGE-A11 were investigated using FLAG-MAGE and HA-
tagged p107 fragments. p107 NH2-terminal fragments (1–180)
and (1–385), carboxyl-terminal fragment (385–1068) contain-
ing the pocket region, and 409–826 with the pocket region
deleted each associated with FLAG-MAGE (Fig. 4B, lanes
9–12) similar to full-length p107 (lane 8). FLAG-MAGE inter-
actedwith endogenous p107 inHEK293 cells (Fig. 4C) that have
relatively high levels of p107 (see Fig. 12A). FLAG-MAGE also
associated with endogenous E2F1 and E2F4 transcription fac-
tors important in cell cycle control (Fig. 4B, lanes 7–12).
The results suggest that MAGE-A11 interacts with multi-
ple regions of p107 to modulate AR transcriptional activity.
The association of MAGE-A11 with endogenous p107 and
endogenous E2Fs places it in important cell growth regula-
tory pathways.
MAGE-A11 Stabilizes p107 and Modulates Ubiquitination—
The effect of MAGE-A11 on p107 was investigated in stability
studies. MAGE-A11 increased p107 levels in cells treated with
or without EGF (Fig. 5A) but did not increase p130 (B). A sec-
ond, more slowly migrating form of p107 was evident with the
coexpression of MAGE-A11 (Fig. 5, A and B). Both full-length
MAGE-A11 and the (112–429) carboxyl-terminal fragment that
interacted with p107 (Fig. 2) associated with the fast- and slow-
migrating forms of p107. However, MAGE-A11 fragments 112–
307 and 112–298 had no effect on p107 levels (Fig. 5C).
The apparent stabilization of p107 byMAGE-A11was inves-
tigated further by inhibiting protein synthesis using cyclohexi-
mide. In these experiments, p107was detected in a time-depen-
dent manner only when MAGE-A11 was expressed (Fig. 5D,
lanes 1–8). p107migrated as twodistinct bandswhose intensity
declined with time, similar to MAGE-A11. There was a time-
dependent shift from the faster-migrating to the slower-mi-
grating form of p107. Treatment of cell extracts with  protein
phosphatase did not alter the double-band migration of p107
(data not shown), which indicates that phosphorylationwas not
responsible. Immunoprecipitation of p107 from cells express-
ing FLAG-ubiquitin demonstrated that p107 undergoes ubiq-
uitination in association with the stabilizing effects of MAGE-
A11 (Fig. 5E).MAGE-A11 appeared to inhibit ubiquitination of
p107.
These results suggest that MAGE-A11 stabilizes p107 by
inhibiting ubiquitination. The specificity of MAGE-A11 stabi-
lization of p107 provided further evidence that MAGE-A11
interacts preferentially with p107 of the Rb family.
MAGE-A11 Activates E2F Transcriptional Activity—The
association of endogenous E2F1 and E2F4 with FLAG-MAGE
FIGURE 2. MAGE-A11 interacts with p107 and Rb but not p130. pCMV-FLAG (), pCMV-FLAG-MAGE, or FLAG-MAGE-(112– 429) (5 g) was expressed in COS1
cells with 5 g of CMV-p107 (A), pCMV-hRb (B), or pcDNA3-p130 (C). Cells were incubated for 24 h in serum-free medium containing 0.1 g/ml EGF and
harvested in immunoprecipitation lysis buffer without deoxycholate or glycerol. Cell extracts (50 g of protein/lane, right) and immunoprecipitates (IP, left)
were probed using p107, Rb, p130, and MAGE-A11 antibodies. Arrows, p107, Rb, p130, FLAG-MAGE, and IgG.
FIGURE 3. MAGE-A11 mediates AR interaction with p107. pCMV-FLAG (4
g) and 2 g of CMV-p107 or 4 g of pCMV-FLAG-AR with or without 2 g of
pCMV5 (p5), 2 g of CMV-p107, and/or 2 g of pSG5-MAGE was expressed in
COS1 cells. Cells were incubated with or without 10 nM DHT and 0.1 g/ml
EGF for 24 h before harvest. Cell extracts (40 g of protein/lane) and immu-
noprecipitates (IP, top) were probed using p107, MAGE-A11, and AR32
antibodies.
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(Fig. 4B) suggests thatMAGE-A11 interacts with additional cell
cycle regulatory proteins influenced by phosphorylation (45).
Immunoprecipitation studies of endogenous E2F1 inCOS1 and
HeLa cells showed that FLAG-MAGE associated with a faster-
migrating form of endogenous E2F1 (Fig. 6A, lanes 4 and 6).
MAGE-A11 interaction with hypophosphorylated E2F1 was
confirmed by the shift to the faster-migrating form after treat-
ment with  protein phosphatase (Fig. 6B). The results show
FIGURE 4. MAGE-A11 interacts with multiple regions of p107, endogenous p107, and endogenous E2Fs. A, schematic of human p107 protein interaction
domains. B, pCMV-FLAG or pCMV-FLAG-MAGE (4 g) was expressed in COS1 cells with 1 g of full-length CMV-p107-(1–1068), CMV-HA-p107-(1–180), or
CMV-HA-p107-(1–385) or 3 g of CMV-HA-p107-(385–1068) or CMV-HA-p107409 – 826. Cells were incubated for 24 h in serum-free medium containing 0.1
g/ml EGF. Immunoprecipitates (IP, top panel) and cell extracts (40 g of protein/lane, bottom panel) were probed using p107, HA, and MAGE-A11 antibodies.
Endogenous E2F4 and E2F1 were detected using E2F4 (sc-512) and E2F1 (sc-251) antibodies. C, pCMV-FLAG or pCMV-FLAG-MAGE (3 g) was expressed in
HEK293 cells. Cells were incubated for 24 h before harvest in serum-free medium containing 0.1 g/ml EGF and 1 M MG132 proteasome inhibitor. Immuno-
precipitates (top panel) and cell extracts (150 g, center and bottom panels) were probed for endogenous p107 and FLAG-MAGE.
FIGURE 5. MAGE-A11 interacts with endogenous p107, stabilizes p107, and modulates p107 ubiquitination. A, pCMV5 or CMV-p107 (2 g) was
expressed in COS1 cells in 10-cm dishes with or without 2 g of pSG5-MAGE. Cells were incubated for 24 h in serum-free medium with or without 0.1 g/ml EGF.
Cell extracts prepared in immunoblot lysis buffer (40 g of protein/lane) were probed using p107 and MAGE-A11 antibodies. B, CMV-p107 (3 g), 3 g of
pCMV5 (), or 3 g of pcDNA3-p130 was expressed in COS1 cells in 6-cm dishes with or without 1 g of pSG5-MAGE. Cells were incubated for 24 h in serum-free
medium with 0.1 g/ml EGF. Cell extracts (40 g of protein/lane) prepared in immunoblot lysis buffer were probed using p107, p130, and MAGE-A11
antibodies. C, pCMV5 (2 g) alone () or 2 g of CMV-p107 with or without 100 ng of WT pSG5-HA-MAGE-(2– 429), 25 ng of pSG5-HA-MAGE-(112– 429), 50 ng
of pSG5-HA-MAGE-(112–307), or 100 ng of pSG5-HA-MAGE-(112–298) were expressed in COS1 cells in 10-cm dishes. Cells were incubated for 24 h in serum-free
medium. Cell extracts (40 g of protein/lane) prepared in immunoblot buffer were probed on transblots using p107 and HA antibodies. D, CMV-p107 (2 g)
and/or 2 g of pSG5-MAGE were expressed in COS1 cells in 10-cm dishes. Cells were incubated for 24 h in serum-free medium. The next day, medium was
exchanged, and cells were treated with 5 M cycloheximide. Cells were harvested at 0, 8, 16, and 24 h in immunoblot lysis buffer. Cell extracts (50 g of
protein/lane) were probed using p107 and MAGE-A11 antibodies. E, pCMV-FLAG (6 g) or 6 g of pCMV-FLAG-ubiquitin (FLAG-Ub) was expressed in COS1 cells
with or without 1 g of pSG5-MAGE and/or 3 g of CMV-p107. Cells were incubated for 24 h in serum-free medium containing 0.1 g/ml EGF and immuno-
precipitated using FLAG antibody affinity resin. Transblots of immunoprecipitates (IP, top panels) and cell extracts (40 g of protein/lane, bottom panels) were
probed using p107 and MAGE-A11 antibodies.
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that MAGE-A11 interacts with hypophosphorylated E2F1 and
not with hyperphosphorylated E2F1.
A MAGE-A11-dependent release of active E2Fs from p107
or Rb would be expected to increase E2F transcriptional activ-
ity. This possibility was tested by expressing MAGE-A11 with
E2F1-Luc, an E2F1-responsive luciferase reporter gene that
contains the 728 nucleotide E2F1 promoter region (38).
Increased expression of MAGE-A11 caused a dose-dependent
increase in E2F1-Luc transactivation (Fig. 7A). The MAGE-
A11-dependent increase in E2F1-Luc transactivation was sim-
ilar to that seen with E1A (Fig. 7B), an early adenoviral protein
that interacts with Rb-related proteins and releases transcrip-
tionally active E2Fs (29). Multiple inactivatingmutations in the
E2F1 response element region of E2F1-Luc in E2F1-Luc(-E2F)
that disrupted activation by E2F1 (38) eliminated activation by
MAGE-A11 or E1A (Fig. 7B, right).
The specificity of MAGE-A11 activation of the two major
classes of E2Fs was tested using E2F1-Luc and E2F4-Luc, where
the latter contains a 3-kb E2F4 promoter region that is activated
by E2F4 (38). Studies were performed with or without p300 on
the basis of the synergistic actions of MAGE-A11 and p300 (4).
MAGE-A11 increased transactivation of E2F1-Luc and E2F4-
Luc to a similar extent, but the synergy between MAGE-A11
and p300 was greater for E2F1-Luc (Fig. 7C).
Several previously characterized MAGE-A11 mutations dis-
rupt amino acid residues critical for steroid receptor coregula-
tor activity (2–4, 13). Some of these site-specific mutants were
tested for their effects on E2F1 transactivation. The synergistic
effect of MAGE-A11 and p300 on E2F1-Luc transactivation
was diminished with MAGE-I188A,F189A, in which the p300
interaction site was disrupted (Fig. 7D). This finding suggests
that the synergy betweenMAGE-A11 and p300 in E2F transacti-
vation depends on MAGE-A11 interaction with p300. The NH2-
terminal deletion mutant MAGE-(111–429), Chk1 kinase phos-
phorylation site mutant T360A, monoubiquitination site
mutant K240A,K245A, and hydrophobic F-box mutants
L358A, L359A and V368A,L369A, which express at levels sim-
ilar to the wild type (4, 10, 13), each inhibitedMAGE-A11 acti-
vation of E2F1-Luc (Fig. 7E).
These results suggest that the interaction of MAGE-A11 with
p107 releases transcriptionally active E2Fs, similar to adenovirus
oncoprotein E1A. MAGE-A11 interaction with hypophosphory-
FIGURE 6. MAGE-A11 interacts with hypophosphorylated E2F1. A, pCMV-
FLAG (3 g) () or 3 g of pCMV-FLAG-MAGE was expressed in COS1 cells
(1.8  106 cells/10-cm dish, left) using DEAE-dextran and 2 g of pCMV-FLAG
() or pCMV-FLAG-MAGE in HeLa cells (7.5  105 cells/10-cm dish, right) using
FuGENE 6 (Roche Applied Science). Cell extracts (40 g of protein/lane) and
immunoprecipitates (IP) were probed using MAGE-A11 antibody and E2F1
(sc-251) antibody for endogenous E2F1. B, pSG5-MAGE (2 g) was expressed
in COS1 cells with or without 2 g of CMV-E2F1. Cells were incubated with 0.1
g/ml EGF and 1 M MG132 proteasome inhibitor for 24 h before harvest in
immunoprecipitation lysis buffer without NaF, deoxycholate, sodium vana-
date, or EDTA. Cell extracts (30 g of protein/lane) were treated with or with-
out  protein phosphatase as described under “Experimental Procedures.”
Transblots were probed using E2F1 (sc-193) and MAGE-A11 antibodies.
FIGURE 7. MAGE-A11 activates endogenous E2F1. A, pSG5 (100 ng) () or 2, 10, 25, or 100 ng of pSG5-MAGE was expressed in HeLa cells with 0.1 g of
E2F1-Luc. B, pSG5, pSG5-MAGE, or CMX-E1A (10, 25, 50, or 100 ng) was expressed in HeLa cells with 0.1 g of E2F1-Luc or 0.1 g of E2F1-Luc(-E2F) with
inactivating mutations in E2F1 response elements. C, pSG5 (10 ng) () or 10 ng of pSG5-MAGE was expressed in HeLa cells with or without 100 ng of pSG5 ()
or pSG5-HA-p300 and 0.1 g of E2F1-Luc (left) or 0.1 g of E2F4-Luc (right). D, pSG5 (50 ng) () or 10 ng of pSG5-MAGE WT or I188A,F189A mutant was
expressed in HeLa cells with 0.1 g of E2F1-Luc with or without 50 ng of pSG5 () or pSG5-HA-p300. E, pSG5 (0.1 g) () or 0.1 g of pSG5-MAGE WT or 111-429,
T360A, K240A,K245A, S174A, I188A,F189A, L358A,L359A, or Y368A,L369A mutant was expressed in HeLa cells with 0.1 g of E2F1-Luc. Luciferase activity is the
mean  S.D. (error bars) representative of three experiments.
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lated E2F1 is consistent with the release of active hyperphosphor-
ylated E2F1. Amino acid residues important for steroid receptor
coregulatory activity were required for MAGE-A11 to increase
E2F transcriptional activity.
Transcriptional Regulation by MAGE-A11 and p107—The
influence ofMAGE-A11 on transcriptional activator or repres-
sor activity of p107 was explored further by determining the
effects of MAGE-A11 and p107 on E2F1-Luc transactivation.
Synergy between MAGE-A11 and p300 and between E1A and
p300 in E2F1-Luc transactivation was inhibited by p107 in
HeLa cells (Fig. 8, A and B). p107409–826 (DE), in which the
pocket region was deleted, inhibited MAGE-A11 activation of
E2F1-Luc less than full-length p107, and p130 did not inhibit
E2F1-Luc transactivation by MAGE-A11 (Fig. 8C).
In LAPC-4 cells, E2F1 or E1A activated E2F1-Luc to a greater
extent than MAGE-A11 (Fig. 9A), possibly because of higher
endogenous MAGE-A11 levels in LAPC-4 cells. When E2F1
expression was inhibited using siRNA (Fig. 9B), transactivation
of E2F1-Luc by expressed or endogenous E2F1was inhibited (C
and D). However, increasing p107 did not inhibit, and slightly
increased, E2F1-Luc transactivation in LAPC-4 cells (Fig. 9E).
These results suggest that transcriptional repression by p107
in HeLa cells that have low levels of MAGE-A11 is lost in
LAPC-4 cells with higher MAGE-A11. The cellular environ-
ment of LAPC-4 cells that includes higherMAGE-A11 contrib-
utes to the transcriptional activator activity of p107.
Regulation of an endogenous E2F1-dependent Gene—p27 is a
cyclin-dependent kinase inhibitor and tumor suppressor that
inhibits theG1-to-S phase transition of the cell cycle (46). p27 is
transcriptionally up-regulated by E2F1 (47, 48), but its levels are
often low in advanced prostate cancer (49, 50). In agreement
with this finding, endogenous p27 proteinwas almost undetect-
able in LAPC-4 cells, but its levels increased slightly in a dose-
dependent manner in response to DHT (Fig. 10A, left). The
DHT-dependent increase in p27 protein was more evident in
cells treated with MG132, a proteasome inhibitor (Fig. 10A,
right), and there was a transient increase in p27 mRNA in
response to DHT (B).
The apparent rapid degradation of p27 mRNA and/or pro-
tein in LAPC-4 cells was consistent with the faster LAPC-4 cell
growth in the presence of 1 or 10 nM DHT (Fig. 10C) and the
increase in p27 protein with AR and MAGE-A11 lentivirus
shRNA knockdown (D). The increase in p27 with AR or
MAGE-A11 knockdownmay reflect, in part, the dependence of
LACP-4 cell growth onAR andMAGE-A11 (10) because loss of
AR signaling can arrest androgen-dependent prostate cancer
cells in G0/G1 phase of the cell cycle (51). The results suggest
that AR and MAGE-A11 are involved in the regulation of
endogenous p27.
MAGE-A11 Links E2F1 and p107 for Transcriptional
Activation—Controversy regarding p107 associationwith E2F1
in transcriptional activation or repression (52–54) led us to
determine the effects of MAGE-A11 on E2F1 interaction
with p107. E2F1 was stabilized by MAGE-A11 (Fig. 11A),
similar to the effect of MAGE-A11 on p107 (Fig. 5A). E2F1
was not detected without expression of MAGE-A11 (Fig.
11A, lanes 4 and 5) but was readily detected in an EGF-de-
pendent manner when MAGE-A11 was expressed (Fig. 11A,
lanes 6 and 7).
Stabilization of E2F1 and p107 byMAGE-A11 raised the pos-
sibility thatMAGE-A11 links these regulatory proteins, as seen
for AR and p107. Immunoprecipitation studies showed that
E2F1 strongly associated with FLAG-p107 in the presence of
MAGE-A11 (Fig. 11B). Endogenous E2F1 also associated with
FLAG-p107 in LAPC-4 cells, although endogenous MAGE-A11
was too low for detection in the immunoprecipitate (Fig. 11C).
To obtain further evidence for p107 transcriptional activator
activity in prostate cancer, the effect of p107 knockdown was
assessed in LAPC-4 cells. p107 was detected in LAPC-4 cell
extracts at levels similar to CWR-R1 and LNCaP prostate can-
cer cells andwas not significantly different from levels in benign
human prostate epithelial PWR-1E and RWPE-2 cells or CV1
or COS1 cells but greater than HeLa or HeLa cells expressing
the AR (Fig. 12A). HEK-293 cells had the highest endogenous
p107 (Fig. 12A, lane 18). ARwas detected in prostate cancer and
HeLa cells stably expressing AR (Fig. 12A, lanes 3–10). E2F1
was detected in all cell types examined. However, the mobility
of E2F1 differed between benign and cancer cells that suggested
differences in phosphorylation. E2F1 migrated as two major
bands in prostate cancer cells (Fig. 12A, lanes 5–10) but as the
single faster-migrating hypophosphorylated form in PWR-1E
and RWPE-2 benign prostate cells (lanes 11–14). Our earlier
FIGURE 8. p107 inhibits MAGE-A11 activation of E2F1 in HeLa cells. A, pSG5 (25 ng) () or 25 ng of pSG5-MAGE was expressed in HeLa cells with 0.1 g of
E2F1-Luc with or without 50 ng of pSG5 () or pSG5-HA-p300 and 10 ng of pCMV5 () or CMV-p107. B, pSG5 (50 ng) alone (), 25 ng of pSG5-MAGE (left), or
25 ng of CMX-E1A (right) was expressed in HeLa cells with 0.1 g of E2F1-Luc with 50 ng of pCMV5 () or 10, 25, or 50 ng of CMV-p107. C, pCMV5 (100 ng) ()
or 100 ng of pSG5-MAGE was expressed in HeLa cells with 0.1 g of E2F1-Luc and 10 ng of pCMV5 (), CMV-p107, CMV-p107409 – 826 (DE) or pcDNA3-p130.
Luciferase activity is the mean  S.D. (error bars) representative of three experiments.
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results (Fig. 6A) showed that MAGE-A11 interacts with the
faster-migrating hypophosphorylated form of E2F1. The E2F1
dimer partner DP-1 was detected in all cell types. MAGE-A11
was detected in LAPC-4 cells that express endogenous AR (Fig.
12A, lanes 9 and 10) and in HeLa cells that stably express AR
(lanes 3 and 4), which suggests that an increase in AR is associ-
ated with an increase in endogenous MAGE-A11.
When p107 levels were lowered using siRNA (Fig. 12B), acti-
vation of E2F1-Luc by expressed or endogenous E2F1 was
inhibited in LAPC-4 cells (Fig. 12, C and D). p107 siRNA-5, 6,
and 9 decreased p107 levels and inhibited E2F1-Luc transacti-
vation, whereas nonspecific siRNA or p107 siRNA-8 did not
alter p107 levels or inhibit E2F1-Luc transactivation.
Immunostaining MAGE-A11 and p107 in representative sam-
ples of benign prostate and prostate cancer showed that MAGE-
A11 and p107 are expressed weakly in stromal and epithelial cells
of benign prostate tissue (Fig. 13, A–D). MAGE-A11 and p107
immunostaining increased in androgen-stimulated prostate can-
cer (Fig. 13, E and F) andwasmost intense in castration-recurrent
prostate cancer (G and H). These results support the hypothesis
thatMAGE-A11 facilitates the transcriptional activator activity of
p107 during prostate cancer progression.
FIGURE 9. Activation of E2F1 in LAPC-4 cells. A, pCMV5 (p5, 50 ng) or 10, 25, 50, or 100 ng of CMV-E2F1, pSG5-MAGE, or CMX-E1A was expressed in LAPC-4 cells
with 0.1 g of E2F1-Luc. B, pCMV5 (1 g) or 1 g of CMV-E2F1 was expressed in COS1 cells in 6-well plates using Lipofectamine 2000 with or without 10 nM
nonspecific siRNA (NS) or E2F1 siRNA-5, -6, -7, or -8. Cell extracts (10 g of protein/lane) prepared in immunoblot lysis buffer were probed on the transblot using
E2F1 (sc-251) antibody. C, pCMV5 (25 ng) () or 25 ng of CMV-E2F1 was expressed in LAPC-4 cells using Lipofectamine 2000 with 0.1 g of E2F1-Luc and 1 nM
nonspecific or E2F1 siRNA. D, pSG5 (150 ng) was expressed in LAPC-4 cells with 0.1 g of E2F1-Luc and 1 nM E2F1 siRNA or two different nonspecific siRNAs.
E, pCMV5 (50 ng) () alone or 50 ng of CMV-E2F1 was expressed in LAPC-4 cells with 0.1 g of E2F1-Luc and 50 ng of pCMV5 () or 10, 25, or 50 ng of CMV-p107.
In A and C–E, luciferase activity is the mean  S.D. (error bars) representative of three experiments.
FIGURE 10. AR and MAGE-A11 regulation of p27 expression. A, LAPC-4 cells grown for 48 h in 5% charcoal-stripped serum medium were incubated for 24 h
in serum-free medium with increasing concentrations of DHT without (lanes 1– 4) or with 1 M MG132 added 24 and 1 h before harvest (lanes 5– 8). Cells were
extracted in immunoblot lysis buffer, and extracts (80 g of protein/lane) were probed on the transblot using purified mouse p27 antibody. B, LAPC-4 cells
placed in serum-free medium for 24 h were transferred to 10% charcoal-stripped serum medium with or without 10 nM DHT for increasing times. RNA was
extracted and analyzed by quantitative real-time RT-PCR as described under “Experimental Procedures.” C, LAPC-4 cell growth was assayed with or without
increasing DHT concentrations as described under “Experimental Procedures.” Data are the mean  S.E. of triplicate measurements. D, immunoblot analysis of
LAPC-4 cell extracts after transduction of cells without lentivirus (NV) or with lentivirus for nonspecific 18-bp control; MAGE-A11 shRNA-827, 947, and 169;
nonspecific empty vector control; and AR5 shRNA. Transblots of cell extracts (40 or 80 g of protein/lane) were probed using AR32, MAGE-A11, and p27 (BD
Biosciences, 1:200) antibodies.
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DISCUSSION
Primate-specific Transcriptional Coregulator MAGE-A11—
Wehave shown thatMAGE-A11 interacts selectivelywith p107
of the Rb family, increases E2F1 transcriptional activity and
contributes to the transcriptional activator function of p107.
Our findings are consistent with the established role of p107 in
cell cycle regulation (24), the cell cycle-dependent expression of
MAGE-A11 (4), the cell growth promoting effects of MAGE-
A11 (10), and the regulation of MAGE-A11 by a cell cycle-de-
pendent kinase (4, 13).
The ability of MAGE-A11 to link p107 to AR and E2F1 and
enhance prostate cancer cell growth suggests that MAGE-A11
is a transcriptional amplifier in primates important in cell cycle
control. siRNA knockdown of p107 in prostate cancer cells
showed that p107 is a transcriptional activator that has lost its
ability to repress AR and E2F1 transcriptional activity. MAGE-
A11 appears to act in a molecular hub for transcription regula-
tion in primates by linking p107 to E2F1 and AR. The increase
inMAGE-A11 (10, 11, 14) and p107 in prostate cancer suggests
thatMAGE-A11 is a proto-oncogene with properties similar to
the adenoviral oncoprotein E1A.
Regulation of p107 by MAGE-A11—The retinoblastoma
family members Rb, p107, and p130 regulate the cell cycle and
have tumor suppressor activity through the modulation of E2F
transcription factors (55–57). Rb is a tumor suppressor,
whereas p107 and p130 are involved in cell cycle regulation
(24). Hypophosphorylated Rb-related proteins interact with
E2Fs and corepressors to actively repress E2F-dependent gene
transcription and cause cell cycle arrest in G0/G1 (58–61).
Mitogen-induced hyperphosphorylation of Rb or p107 by
cyclin-dependent kinases releases active E2Fs to up-regulate
genes involved incell cyclecontrol (18,62).Rb ishypophosphor-
ylated in G0/G1 and phosphorylated during the G1-S transition
(63). p107 levels vary during the cell cycle, are low in G0, and
accumulate during re-entry into S phase (64, 65). p107 associ-
ates with E2Fs and becomes phosphorylated by cyclin-depen-
dent kinases during S phase (24, 66, 67).
We have shown that MAGE-A11 interacts preferentially
with p107 and less with Rb and did not interact with p130.
MAGE-A11 interaction with p107 resulted in stabilization and
time-dependent ubiquitination of p107. MAGE-A11 may be
part of a ubiquitin ligase complex as suggested for another
member of theMAGE family (68).MAGE-A11 itself undergoes
monoubiquitination on lysine residues in theMAGE homology
domain required to stimulate transcriptional activity of human
AR (13), human progesterone receptor-B (2) and E2F1. The
increase in MAGE-A11 and its ability to stabilize p107 may
contribute to the increase in p107 in prostate cancer and its
function as a transcriptional activator.
Rb has been implicated in cross-talk with theARNH2-termi-
nal region (69, 70). Overexpression of Rb increased AR tran-
scriptional activity that was lost in Rb-deficient cells (71). How-
ever, whether Rb has direct effects on AR or indirect effects
through coregulators remains unclear. MAGE-A11 interacts
with the AR NH2-terminal FXXLF motif region and could
mediate the effects of Rb. Our studies suggest that p107 and
possibly Rb are modulated by the AR coregulator MAGE-A11.
Regulation of E2F Transcriptional Activity by MAGE-A11—
E2F transcription factors are DNA binding proteins that recog-
nize the consensus sequenceG/CTTTG/C in promoter regions
of genes that regulate cell cycle entry and exit (72, 73). E2F
binding to DNA is modulated by phosphorylation. Activator or
repressor activity of E2Fs is influenced by interactions with
transcription factors and coregulators (45, 74). E2Fs are nega-
tively regulated by the Rb family (75, 76). Mitogens activate
cyclin-dependent kinases to phosphorylate Rb-like proteins,
release E2Fs, and induce E2F-regulated genes that control cell
exit from G1 and entry into S phase (20). Upon release in
FIGURE 11. MAGE-A11 stabilizes E2F1 and mediates an interaction
between E2F1 and p107. A, pCMV5 (1 g) (lane 1), 1 g of pSG5-MAGE (lanes
2 and 3), 0.5 g of CMV-E2F1 (lanes 4 and 5), or 1 g of pSG5-MAGE and 0.5 g
of CMV-E2F1 together (lanes 6 and 7) was expressed in COS1 cells. Cells were
incubated for 24 h before harvest in serum-free medium with or without 0.1
g/ml EGF. Cell extracts (40 g of protein/lane) were probed on the transblot
using E2F1 (sc-193) and MAGE-A11 antibodies. B, pCMV-FLAG (4 g) () or 4
g of pCMV-FLAG-p107 was expressed in COS1 cells with or without 3 g of
pSG5-MAGE or 4 g of CMV-E2F1 alone or together. Cells were incubated for
24 h in serum-free medium with 0.1 g/ml EGF and immunoprecipitated
using FLAG affinity resin. Transblots of cell extracts (40 g of protein/lane, left)
or immunoprecipitates (IP, right) were probed using p107, E2F1 (sc-193), and
MAGE-A11 antibodies. C, pCMV-FLAG, or pCMV-FLAG-p107 (4 g/dish) was
expressed in three 10-cm dishes plated at 7  106 LAPC-4 cells/dish using
8 l of X-tremeGENE in 160 l of medium added/dish. The next day, cells
were transferred to serum-free medium with 0.1 g/ml EGF and incubated
for 24 h. The cell extract (40 g of protein/lane) prepared in immunopre-
cipitation lysis buffer and immunoprecipitates were probed overnight at
4 °C on transblots using p107 (sc-318, 1:200 dilution) and MAGE-A11 anti-
bodies (15 g/ml). The blot was stripped and reprobed using E2F1 (sc-
193) antibody (1:100 dilution).
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response to mitogen-induced phosphorylation or viral trans-
formation, E2Fs form heterodimeric complexes with the dimer
partner DP-1 or DP-2 (77).
Most E2F-responsive genes regulate DNA synthesis and cell
cycle progression. E2F1, E2F2, and E2F3 are thought to com-
plex primarily with Rb. When activated, they induce entry into
S phase or, depending on their levels, induce apoptosis (78, 79).
E2F1 up-regulates its own expression during the cell cycle (38,
80). E2F4 and E2F5 have repressive activity and are involved in
cell differentiation. E2F4 associates with p107 and E2F5 with
p130 (81–83). E2F6, E2F7 and E2F8 are transcriptional repres-
sors that do not interact with Rb-related proteins (73). E2F1,
E2F2, and E2F3 are predominantly nuclear, whereas E2F4 and
E2F5 are cytoplasmic and nuclear (53). Although p107 is con-
sidered a transcriptional repressor that associates primarily
with E2F4 (84–86) and not with E2F1 (81, 87), recent studies in
addition to our own suggest that p107 can have activator or
repressor activity, with an interaction between p107 and E2F1
modulated during the cell cycle (52).
MAGE-A11 increased the interaction between p107 and
E2F1, which was reported to be weaker than p107 interaction
with E2F4 (88), and enhanced the transcriptional activity of
E2F1. E2F1 is regulated by phosphorylation (89–91).We noted
that a major hyperphosphorylated form of E2F1 in cancer cells
was not evident in benign prostate cells. MAGE-A11 forms a
stable complex with hypophosphorylated E2F1. The faster
migration of E2F1 after treatment with  protein phosphatase
suggests that activation of E2F1 by phosphorylation is associ-
ated with release from MAGE-A11. Similar to E1A, MAGE-
A11 appears to sequester hypophosphorylated E2F1 and pro-
mote the release of activated phosphorylated E2F1 from p107.
MAGE-A11 interaction with E2F transcription factors
resembles, in some respects, othermembers of theMAGE gene
family. Necdin, necdin-like protein 1 (MAGE-L2), and necdin-
like protein 2 (MAGE-G1) are neuron-specific cell growth sup-
pressors whose absence is associated with Prader-Willi syn-
drome and autistic disorders (92). Necdin andMAGE-G1 bind
E2F1 and repress E2F1-dependent gene transcription (93, 94).
We found thatMAGE-A11 stabilized E2F1 and p107 andmedi-
ated an interaction of p107 with AR and E2F1 that caused tran-
scriptional repression or activation, depending on MAGE-A11
levels.
MAGE-A11 activation of E2F1 may promote normal cycling
cells to enter S phase of the cell cycle. A threshold model was
proposed where genes that regulate cell proliferation or apo-
ptosis are induced by different levels of E2F that act as positive
or negative regulators of cell growth (53). Positive and negative
cooperation in gene regulation by AR and E2F1 were reported
in prostate cancer cells (95–97). Relative levels of MAGE-A11
and p107 influence AR and E2F1 transcriptional activation or
repression.
MAGE-A11 and Viral Oncogene E1A—Human adenoviral
early region protein E1A transforms cells indirectly by activat-
ing E2Fs through competitive interaction with Rb-related pro-
teins (27, 28, 98–100). E1A interaction with Rb-related pro-
teins releases active E2F transcription factors that activate
FIGURE 12. Transcriptional activation by p107 in LAPC-4 cells. A, HeLa (106), HeLa-AR3A-PSA-ARE4 (2  106), CWR-R1 (1.5  107), LNCaP (1.2  107), LAPC-4
(9  106), PWR-1E (3  106), RWPE-2 (3  106), CV1 (1.5  106), COS1 (1.5  106), and HEK-293 cells (5  106) were plated in 10-cm dishes in serum-containing
medium. The next day, the medium was changed to 5% charcoal-stripped serum without phenol red. Cells were treated for 48 h with or without 10 nM DHT. Cell
extracts (50 g of protein/lane) were analyzed by probing the transblot using p107, AR32, AR52, E2F1, DP-1, and MAGE-A11 antibodies. B, pCMV5 (p5, 1 g) or
1 g of CMV-p107 was expressed in COS1 cells using Lipofectamine with or without 5 nM nonspecific (NS) siRNAs or p107 siRNA-5, 6, 8, or 9. The transblot of cell
extracts (25 g of protein/lane) was probed using p107 antibody. C, pCMV5 (25 ng) () or 25 ng of CMV-E2F1 was expressed in LAPC-4 cells with 0.1 g of
E2F1-Luc and 10 nM nonspecific siRNA or p107 siRNA-5, 6, 8, or 9 using Lipofectamine 2000. D, E2F1-Luc (0.1 g) was expressed in LAPC-4 cells with 10 nM
nonspecific or p107 siRNA-5, 6, 8, or 9 using Lipofectamine 2000. In C and D, luciferase activity is the mean  S.D. (error bars) representative of three
experiments.
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target genes and cause cell cycle progression (29). E1A inacti-
vates Rb in G0/G1 of the cell cycle, causing exit from G1 and
induction of DNA synthesis in S phase in association with
uncontrolled cell cycle progression and immortalization (27,
101–104). The effect of oncoprotein E1A overrides the inhibi-
tory effects of p16 on cell cycle progression (105).
MAGE-A11 shares a remarkable similarity with E1A.
MAGE-A11 and E1A form strong complexes with p300 (4, 106,
107) and interact with E2F transcription factors (27) and Rb-
related proteins to activate or repress transcription (101, 108).
Like E1A, MAGE-A11 relieves the constraint by p107 on E2F1
promotion of cell cycle progression. MAGE-A11 interaction
with p107 caused a dose-dependent increase in E2F activity
similar to E1A. MAGE-A11 shares a sequence similarity with
E1A and E2F1 motifs that bind the pocket region of Rb-related
proteins. MAGE-A11 amino acid sequence 410DPYSYPD-
LYE419 is similar to E1A 39EPPTLHELYD48, which binds Rb-
related protein pocket regions, and E2F1 417EGEGIRDLFD426
in the transactivation domain.
However, although the primate-specific MAGE-A11 gene is
expressed at very low levels in normal cells and at higher levels
in prostate cancer,E1A is a viral oncogene.NeitherMAGE-A11
nor E1A bind DNA directly (109). E1A interacts indirectly with
promoters of a large number of cell cycle regulatory genes by
stimulatingE2FDNAbindingthrough increasedE2Fphosphor-
ylation (45). E1A interaction with p300 and p107 follows a tem-
poral sequence during cell replication (108), which also may
occur with MAGE-A11. Synergy between MAGE-A11 and
p300 in E2F-dependent gene transcription depends on E2F
response element DNA andMAGE-A11 interaction with p300.
MAGE-A11 also amplifies AR transactivation of androgen-de-
pendent genes (3).
MAGE-A11 in Prostate Cancer—Interactions between Rb-
related proteins and E2Fs are interrupted frequently in cancer,
which result in E2F transactivation of cell cycle regulatory
genes. Almost all cancers functionally inactivate Rb by gene
mutation or deletion, dysregulation by cyclin-dependent
kinases, or sequestration of Rb-related proteins by oncogenic
proteins such as E1A. In agreement with Rb mutations in late-
stage cancer, loss of Rb function is associated with advanced
prostate cancer and increased AR expression (70). E2F1 and
E2F3 increase during prostate cancer progression (110, 111).
Here we provide evidence thatMAGE-A11 is a proto-onco-
gene that disrupts the tumor suppressor function of Rb-related
proteins. MAGE-A11 increases during prostate cancer pro-
gression, enhances AR signaling, and promotes prostate cancer
growth (10, 11, 14). The increase inMAGE-A11 in prostate and
epithelial ovarian cancer results from promoter hypomethyla-
tion, and is associated with early cancer recurrence and poor
survival (112). The cell growth-promoting effects of MAGE-
A11 appear to be mediated through AR signaling and Rb-re-
lated proteins that increase E2F1 transactivation.
Prostate cancer is associated with greater AR sensitivity to
increased levels of coregulators, such as MAGE-A11 (11, 14,
113, 114). The ability of AR andMAGE-A11 to regulate p27, an
important physiological brake on the cell cycle, has implica-
tions for prostate cancer. In LNCaP prostate cancer cells, a
biphasic androgen dose response influences p27 protein levels
where higher DHT increases p27 protein and arrests cell
growth (118, 119). Androgen-dependent changes in protea-
somal degradation have been reported to influence p27 levels
(116, 117). We found that higher DHT concentrations stimu-
lated LAPC-4 cell growth in association with rapid degradation
of p27. The increase in p27 protein in LAPC-4 cells after knock-
down of AR or MAGE-A11 could reflect the loss of androgen-
dependent proteasomal degradation of p27 (115, 120) and the
dependence of prostate cancer cells on androgen-stimulated
growth.
The biphasic LNCaP cell growth response to androgen has
been linked previously to the Rb and E2F pathways (119).
Increased LNCaP cell growth in response to 0.1 nM R1881 was
attributed to increased hypophosphorylated Rb. With 10 nM
R1881, increased p27 protein inhibited cyclin-dependent
kinase phosphorylation of Rb (119). An increase in E2F1 at low
androgen levels was inhibited at higher androgen levels. Our
findings suggest that MAGE-A11 contributes to androgen and
E2F1 regulation of p27.
Increased AR expression may be a molecular basis for pros-





















FIGURE 13. MAGE-A11 and p107 immunostaining in benign prostate and
prostate cancer. Adjacent formalin-fixed, paraffin-embedded sections of
benign prostate-14C (A and B) and 4740 (C and D), androgen-stimulated pros-
tate cancer MS99-10751-198 (E and F), and castration-recurrent prostate can-
cer MS97-11832-2 (G and H) were immunostained using affinity-purified
MAGE-(94 –108) rabbit polyclonal anti-peptide antibody (6 g/ml) (left) and
affinity-purified p107 C-18 (sc-318) rabbit polyclonal antibodies (1:100) (right)
as described under “Experimental Procedures.” Brown positive reaction prod-
uct is shown against toluidine blue staining. The original magnification is
60.
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increases during prostate cancer progression in an inverse rela-
tionship with AR mRNA (14). A subset of castration-recurrent
prostate cancer specimens had 1000-fold higher MAGE-A11
mRNA, whereas AR mRNA was undetectable. p107 was also
increased in castration-recurrent prostate cancer. These find-
ings suggest thatMAGE-A11 not only functions synergistically
with AR and could compensate for lower levels of AR but also
contributes to the activator function of p107. The increase in
primate-specific expression of MAGE-A11 in prostate cancer
facilitates AR transactivation and the inappropriate activation
of E2F1 through selective interaction with Rb-related protein
p107.
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